Project Grant HT94252410290
Award Date
7/30/24
Completion Date
7/29/27
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The University of Oklahoma Health Sciences Center was awarded a $1,144,000 federal Project Grant under the Military Medical Research and Development program (CFDA 12.420) by the Defense Health Agency. The grant, awarded on May 1, 2025, will fund research focused on developing a novel drug therapy that targets the ORP4 protein as a precision treatment for ovarian cancer. The research aims to transform healthcare for military service members and the broader public by investigating innovative...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
The University of Oklahoma Health Sciences Center was awarded a $541,837 federal Project Grant under the Military Medical Research and Development program (CFDA 12.420), administered by the Defense Health Agency. The grant, awarded on May 1, 2025, will fund research to develop a drug targeting the ORP4 protein as a precision treatment for ovarian cancer. The research aims to transform healthcare for military service members and the general public by investigating innovative approaches to disease...
The Department of Defense's Defense Health Agency awarded Duke University a $1,344,946 Project Grant on September 1, 2023 through the Military Medical Research and Development program (CFDA 12.420). This grant supports a 3-year research project titled "Understanding Heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era." The research aims to advance understanding and treatment of prostate cancer, with a focus on improving clinical outcomes for...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
This federal Project Grant award, valued at $1,848,000.00 and provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of Minnesota aimed at therapeutically targeting aberrant mRNA polyadenylation in lethal prostate cancer. The 3-year grant, running from July 1, 2025 to June 30, 2028, will enable the University of Minnesota to conduct advanced biomedical investigations into innovative approaches for...
The Department of the Army Medical Command awarded a $1,402,500 project grant to the Institute For Cancer Research at Temple University-Of The Commonwealth System Of Higher Education to investigate the impact of social determinants of health on quality of life and treatment decision-making in advanced prostate cancer. Funded under the Military Medical Research and Development program (CFDA 12.420), this three-year award beginning June 1, 2022 will support research to transform military and...
The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program provides $1,759,708.00 to Iowa State University of Science and Technology to develop high-throughput, high-resolution in vitro models of prostate cancer bone marrow metastases. The research aims to transform healthcare for military service members and the public by advancing fundamental understanding and treatment of prostate cancer, a significant health...